Німеччина - німецька - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

zoetis deutschland gmbh (4402304) - felines panleukopenievirus, lebend; felines rhinotracheitisvirus, lebend; felines calicivirus, lebend - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - felines panleukopenievirus, lebend (35474) 1000 gewebekultur-infektiöse-dosis 50%; felines rhinotracheitisvirus, lebend (35475) 100000 gewebekultur-infektiöse-dosis 50%; felines calicivirus, lebend (35476) 316227,766 gewebekultur-infektiöse-dosis 50% - katze

Бельгія - німецька - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international - panleucopenie feline parvovirus, live; feline rhinotracheitis-herpes-virus; calicivirus felines, live - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - panleucopenie feline parvovirus, live ; feline rhinotracheitis-herpes-virus ; calicivirus felines, live - feline panleucopenia virus / parvovirus + feline rhinotracheitis virus + feline calicivirus - katze

Австрія - німецька - AGES (Agentur für Gesundheit und Ernährungssicherheit)

richter pharma ag - felines calicivirus (fcv); panleukopenievirus, felin; rhinotracheitisvirus, felin -

Європейський Союз - німецька - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Бельгія - німецька - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eli lilly benelux - feline rhinotracheitis-herpes-virus; panleucopenie feline parvovirus, live; calicivirus felines, live - lyophilisat und lösungsmittel zur herstellung einer injektionslösung - feline rhinotracheitis-herpes-virus ; panleucopenie feline parvovirus, live ; calicivirus felines, live - feline panleucopenia virus / parvovirus + feline rhinotracheitis virus + feline calicivirus + chlamydia - katze

Бельгія - німецька - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eli lilly benelux - feline chlamydophila (= chlamydia psittaci); feline rhinotracheitis-herpes-virus; panleucopenie feline parvovirus, live; calicivirus felines, live - lyophilisat und lösungsmittel zur herstellung einer injektionslösung - feline chlamydophila (= chlamydia psittaci) ; feline rhinotracheitis-herpes-virus ; panleucopenie feline parvovirus, live ; calicivirus felines, live - feline panleucopenia virus / parvovirus + feline rhinotracheitis virus + feline calicivirus + chlamydia - katze

Німеччина - німецька - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dr. förster gmbh - rosmarinöl 12.5g - medizinisches Ölbad

Європейський Союз - німецька - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Європейський Союз - німецька - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Європейський Союз - німецька - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.